Teva launches a generic contraceptive product – the capital market

Teva has launched a generic version of NuvaRing designed to prevent pregnancy, which is based on a combination of hormones. This is a significant product whose sales in the United States last year totaled $ 837 million.

There is already a generic competitor in the market with Amneal with a version called EluRyng. The potential scope of the market does give an indication of the size of the market, but given that the generic product will be at significantly lower prices than the original products, and given the generic competitor already in the market, then even if the market share is significant these may reach up to $ 200 million It is likely to be up to $ 100 million a year.

The product includes a combination of the female hormones progestin and estrogen. The generic version is one of the products on the market out of several products, with Teva having 40 generic products in the women’s health product basket.